2-苄基-6-甲基-4(3H)-嘧啶酮 | 16673-85-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-苄基-6-甲基-4(3H)-嘧啶酮
• 英文名称: 2-benzyl-6-methylpyrimidin-4(3H)-one
• 英文别名: 2-Benzyl-6-methyl-4(3H)-pyrimidinone；2-benzyl-4-methyl-1H-pyrimidin-6-one
• CAS: 16673-85-1
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: DTAMCJGTKKZYAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-苄基-6-甲基-4(3H)-嘧啶酮 在 三氯氧磷 作用下， 反应 1.5h， 以84%的产率得到2-benzyl-4-chloro-6-methylpyrimidine
  参考文献：
  名称：

  Heterocyclic Amplifiers of Phleomycin. VII. Phenyl-, Tolyl-, Phenoxy- and Benzyl-pyrimidines; also Some Carbocyclic Analogues

  摘要：

  本文介绍了 5-苯基、5-对氯苯基、2-对甲苯基、2-和 4-苄基以及 4-苯氧基嘧啶的合成路线，每种嘧啶都带有与硫、氮或氧相连的碱性侧链；还介绍了类似联苯和二苯基甲烷的合成路线。需要对这些化合物进行评估，以确定其是否可作为博来霉素的放大剂。

  DOI：

  10.1071/ch9850825
• 作为产物：
  描述：

  methyl phenylacetimidate hydrochloride 在 sodium hydroxide 、 氨 作用下， 以 乙醇 为溶剂， 反应 60.0h， 生成 2-苄基-6-甲基-4(3H)-嘧啶酮
  参考文献：
  名称：

  Heterocyclic Amplifiers of Phleomycin. VII. Phenyl-, Tolyl-, Phenoxy- and Benzyl-pyrimidines; also Some Carbocyclic Analogues

  摘要：

  本文介绍了 5-苯基、5-对氯苯基、2-对甲苯基、2-和 4-苄基以及 4-苯氧基嘧啶的合成路线，每种嘧啶都带有与硫、氮或氧相连的碱性侧链；还介绍了类似联苯和二苯基甲烷的合成路线。需要对这些化合物进行评估，以确定其是否可作为博来霉素的放大剂。

  DOI：

  10.1071/ch9850825

文献信息

• Modulators of chemokine receptor activity
  申请人：——

  公开号：US20030008893A1

  公开（公告）日：2003-01-09

  Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein. 1

  本文描述了特别是具有式（I）的双环二胺化合物作为趋化因子CCR2和CCR3受体的拮抗剂，包括药物组成和用途，用于治疗或预防与单核细胞聚集、淋巴细胞聚集或白细胞聚集相关的疾病。
• Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives
  作者：Gurram R Madhavan、Ranjan Chakrabarti、Reeba K Vikramadithyan、Rao N.V.S Mamidi、V Balraju、B.M Rajesh、Parimal Misra、Sunil K.B Kumar、Braj B Lohray、Vidya B Lohray、Ramanujam Rajagopalan

  DOI：10.1016/s0968-0896(02)00107-4

  日期：2002.8

  A series of pyrimidinone derivatives of thiazolidinediones were synthesized. Their biological activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPARgamma transactivation assay was performed in HEK 293T cells. PMT13 showed the best biological activity in this series. PMT13 (5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl]thiazolidine-2

  合成了一系列噻唑烷二酮的嘧啶酮衍生物。在胰岛素抵抗，高血糖和肥胖的db / db小鼠中评估了它们的生物学活性。在HEK 293T细胞中进行了体外PPARγ激活测定。PMT13在该系列中表现出最好的生物活性。PMT13（5- [4- [2- [2-乙基-4-甲基-6-氧代-1,6-二氢-1-嘧啶基]乙氧基]苯基甲基]噻唑烷-2,4-二酮）血浆葡萄糖水平更高， db / db小鼠的甘油三酸酯和胰岛素降低活性高于罗格列酮和吡格列酮。PMT13显示出比标准化合物更好的PPARγ反式激活。Wistar大鼠的药代动力学研究表明，PMT13具有良好的全身性暴露。在Wistar大鼠中进行的28天口服毒性研究未显示任何与治疗相关的不良反应。
• Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
  申请人：Dr. Reddy's Research Foundation

  公开号：US06310069B1

  公开（公告）日：2001-10-30

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

  本发明涉及新型抗糖尿病化合物及其互变异构体、衍生物、立体异构体、多晶形态、药用可接受盐、药用可接受溶剂和含有它们的药用可接受组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮衍生物及其药用可接受盐、药用可接受溶剂和含有它们的药用组合物。
• Heterocyclic compounds, process for their preparation and pharmaceutical
  申请人：Dr. Reddy's Research Foundation

  公开号：US05885997A1

  公开（公告）日：1999-03-23

  The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

  本发明涉及新型抗糖尿病化合物，它们的互变异构形式，它们的衍生物，它们的立体异构体，它们的多晶形态，它们的药学上可接受的盐，它们的药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。本发明特别涉及一般式（I）的新型噁唑烷二酮衍生物，以及它们的药学上可接受的盐、药学上可接受的溶剂和含有它们的药用组合物。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES, LEUR PROCEDE DE PREPARATION, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET UTILISATION DE CES COMPOSES DANS LE TRAITEMENT DU DIABETE ET DES MALADIES ASSOCIEES
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1997041097A2

  公开（公告）日：1997-11-06

  (EN) The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.(FR) La présente invention se rapporte à des nouveaux composés antidiabétiques, aux formes tautomères, aux dérivés, aux stéréo-isomères et aux polymorphes de ces composés, aux sels et aux solvates de ces composés, acceptables sur le plan pharmacologique, ainsi qu'aux compositions les contenant et acceptables sur le plan pharmaceutique. L'invention concerne notamment des nouveaux dérivés azolidinediones de la formule générale (I), ainsi que les sels et solvates de ceux-ci, acceptables sur le plan pharmacologique, et les compositions pharmaceutiques contenant ces dérivés.

  本发明涉及新型抗糖尿病化合物、它们的互变异构体、它们的衍生物、它们的立体异构体、它们的多晶形态、它们的药学上可接受的盐、它们的药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明特别涉及一般式(I)的新型噁唑烷二酮衍生物及其药学上可接受的盐、药学上可接受的溶剂和含有它们的制药组合物。

表征谱图